Related references
Note: Only part of the references are listed.The Effect of Antipsychotics on the High-Affinity State of D2 and D3 Receptors A Positron Emission Tomography Study With [11C]-(+)-PHNO
Ariel Graff-Guerrero et al.
ARCHIVES OF GENERAL PSYCHIATRY (2009)
HRRT Versus HR plus Human Brain PET Studies: An Interscanner Test-Retest Study
Floris H. P. van Velden et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study
Ariel Graff-Guerrero et al.
NEUROPSYCHOPHARMACOLOGY (2009)
In Vivo Quantification of Regional Dopamine-D3 Receptor Binding Potential of (+)-PHNO: Studies in Non-Human Primates and Transgenic Mice
Eugenii A. Rabiner et al.
SYNAPSE (2009)
Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia:: A triple tracer PET study
David Mamo et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390
Jesper Ekelund et al.
MOLECULAR IMAGING AND BIOLOGY (2007)
Consensus nomenclature for in vivo imaging of reversibly binding radioligands
Robert B. Innis et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2007)
Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C)-(+)-PHNO is a D3 receptor preferring agonist in vivo
Rajesh Narendran et al.
SYNAPSE (2006)
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor
Freddy Jeanneteau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
An automated method for the extraction of regional data from PET images
Pablo Rusjan et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2006)
Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography
N Ginovart et al.
JOURNAL OF NEUROCHEMISTRY (2006)
A dose-finding study of duloxetine based on serotonin transporter occupancy
A Takano et al.
PSYCHOPHARMACOLOGY (2006)
Synthesis and SAR of highly potent and selective dopamine D3-receptor antagonists:: Variations on the 1H-pyrimidin-2-one theme
H Geneste et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO
M Willeit et al.
BIOLOGICAL PSYCHIATRY (2006)
Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes
MLP Gross et al.
LABORATORY INVESTIGATION (2006)
In vitro characterisation of the high affinity D2/D3 dopamine agonist (+)PhNO
Christine Parker et al.
NEUROIMAGE (2006)
Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2High and D3High receptors
P Seeman et al.
SYNAPSE (2005)
Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756
J Sóvágó et al.
BRAIN RESEARCH BULLETIN (2005)
Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo Imaging of the dopamine D2 high-affinity state with positron emission tomography
AA Wilson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C]RGH-1756 in the monkey brain
J Sóvágó et al.
NEUROCHEMISTRY INTERNATIONAL (2004)
Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors
F Chaperon et al.
NEUROPHARMACOLOGY (2003)
Imaging human mesolimbic dopamine transmission with positron emission tomography:: I.: Accuracy and precision of D2 receptor parameter measurements in ventral striatum
O Mawlawi et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2001)
Antipsychotic drugs, dopamine receptors, and schizophrenia
P Seeman
CLINICAL NEUROSCIENCE RESEARCH (2001)
Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907)
LA van Vliet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
